Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators.
Dimopoulos MA, et al. Among authors: levin md.
N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Online ahead of print.
N Engl J Med. 2024.
PMID: 39652675